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2 Introduction 
2.1 Obesity 
2.1.1 Definitions of obesity, morbid obesity, and superobesity 
Body-mass index (the weight in kilograms divided by the square of the height in meters) is a 
commonly used measure of obesity. First named the Quetelet Index after Adolphe Quetelet in 
1832, and renamed body-mass index (BMI) in 1972, BMI is widely used in epidemiological 
studies of associations between excess weight and morbidity or mortality (1;2). 
Table 1. Classification of underweight, overweight, and obesity according to the World 
Health Organization (1). 
Classification Body-mass index (kg/m2)  
Underweight <18.5  
Normal range 18.5 – 24.9  
Overweight 25.0  
    Pre-obese 25.0 – 29.9  
    Obese 30.0  
        Obese class I 30.0 – 34.9  
        Obese class II 35.0 – 39.9  
        Obese class III 40.0  
Morbid obesity may be defined as a body weight twice or more the desirable weight based on 
life insurance tables (2). The currently used definition of morbid obesity was developed in 
1991 in a National Institutes of Health (NIH) consensus statement (3). Among other criteria, 
this definition suggested that patients with class III obesity (Table 1) or class II obesity with 
high-risk comorbid conditions may be considered for bariatric surgery. The term superobesity 
was proposed in 1987 as a weight exceeding 225% of estimated ideal weight (4). Later, 
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superobesity was defined as having a BMI >50 kg/m2 (5). In this thesis, superobesity is 
defined as a BMI in the range of 50 – 60 kg/m2, and super-superobesity as a BMI >60 kg/m2, 
as suggested by the American Society for Metabolic and Bariatric Surgery (ASMBS) (6). 
2.1.2 Global and national prevalence trends 
To date, the obesity epidemic has not been reversed in any population through public health 
measures (7). A recent study explored worldwide trends in BMI based on measured weight 
and height from 9.1 million participants and 960 country-years from 1980 to 2008. In adults, 
the mean BMI increased by 0.5 kg/m2 per decade for women and by 0.4 kg/m2 per decade for 
men. Large differences in BMI rises were observed across regions and between sexes. 
Worldwide, in 2008, an estimated 1.46 billion adults had a BMI of 25 kg/m2 or greater, 
including some 500 million obese individuals (8). 
In the United States, the prevalence of obesity exceeds 30% in both women and men, with 
recent prevalence figures of a BMI 40 kg/m2 of 8.1% in women and 4.4% in men (9;10). In 
Norway, the prevalence of obesity is approximately 20% in both women and men (11). In the 
Nord-Trøndelag health study (HUNT), obesity rates increased from 13.6% in women and 
7.8% in men in 1984 – 1986 to 23.2% in women and 22.1% in men in 2006 – 2008 (12). 
Little data are available on the prevalence of severe obesity (e.g. BMI >50 kg/m2) from 
measured weight and height (13). In adults, self-reported weight is systematically under-
reported and height is over-reported (14). Data from telephone surveys in the United States 
indicate that the prevalence of severe obesity among adults has increased several times faster 
than the prevalence of overweight and of moderate obesity. For example, the prevalence of a 
BMI >50 kg/m2 increased by 75% from 2000 to 2005, compared to a 24% increase in the 
prevalence of a BMI >30 kg/m2 (15;16).  
In large case series of patients undergoing bariatric surgery in the United States, about 20 – 
25% of patients had preoperative BMIs in the range of 50 – 60 kg/m2 (17-19). In a database of 
patients undergoing bariatric surgery at Oslo University Hospital Aker, about 20% were 
superobese before surgery (unpublished data). 
Although rates of overweight and obesity have increased in children and adults over the last 
decades (8;20), some recent studies indicate that the obesity prevalence is plateauing and 
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possibly decreasing, particularly in women and children (9;21-24). 
2.1.3 Impact on health 
Overall, the disease burden attributable to excess weight is dominated by cardiovascular 
disease, diabetes, and cancer (25). According to projected obesity trends in the United States 
and the United Kingdom, millions of additional cases of these preventable diseases may place 
a serious strain on health systems (26). 
Obesity in childhood is associated with an increased risk for obesity in adolescence and 
adulthood (27;28), and for diabetes and coronary heart disease in adulthood (29-31). As a 
strong association exists between obesity, glucose intolerance, and hypertension in childhood 
and increased rates of premature death, prevention of obesity should start at an early age (32). 
However, little data are available on the effectiveness of intervention programs for overweight 
children and adolescents (33;34). 
Common comorbid conditions and the metabolic syndrome 
In adults, elevated BMI is associated with subsequent development of comorbid conditions 
such as type 2 diabetes mellitus, hypertension, hyperlipidemia, gallbladder disease, and 
osteoarthritis (35-38). This risk is also increased in subjects with a BMI in the upper part of 
the healthy BMI range (22 – 25 kg/m2) (39). A positive association between BMI and the risk 
for ischemic stroke is described regardless of sex and race, but this relationship is attenuated 
after adjusting for diabetes and hypertension (40). In the National Health and Nutrition 
Examination Survey (NHANES, 1999 – 2004), the largest increase in the prevalence of 
hypertension, dyslipidemia, and the metabolic syndrome in obese class III were observed in 
the age group of individuals between 18 and 29 years (41). 
The metabolic syndrome is a constellation of common disorders which confer increased risk 
for type 2 diabetes, cardiovascular disease, and increased all-cause and cardiovascular 
mortality (42-44). A commonly used definition of the metabolic syndrome, published by the 
National Cholesterol Education Program (NCEP), proposes cutoff values for waist 
circumference, triglyceride levels, low levels of high-density lipoprotein (HDL) cholesterol, 
blood pressure, and fasting glucose (42). The prevalence of the metabolic syndrome increases 
with the degree of obesity in children and adolescents (45). In the United States, the 
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prevalence of the metabolic syndrome was 27% in adults in NHANES data from 1999 – 2000 
(46). In a Norwegian cohort of patients eligible for bariatric surgery, 80% had the metabolic 
syndrome as evaluated by the same definition (47). 
Other obesity-related disorders 
In population studies, BMI is positively associated with an increased risk for gastrointestinal 
symptoms, such as gastroesophageal reflux, vomiting, upper abdominal pain, bloating, and 
diarrhea (48-50). Also, morbidly obese patients may have more hiatal hernias and gastritis 
(51). The putative mechanisms for upper gastrointestinal disorders include an increased intra-
abdominal pressure and decreased lower esophageal sphincter pressure in obese individuals 
(52;53). Weight loss is associated with a decreased risk for such symptoms (48). 
An accelerated colonic transit and colonic dysfunction may contribute to an increased 
frequency of diarrhea in obese individuals (49). In a series of 120 patients eligible for bariatric 
surgery (92% women), functional gastrointestinal symptoms were found in 89% of patients, 
18% reported diarrhea, and 10% had fecal incontinence (54). 
Other studies have found positive associations between BMI and sleep-disordered breathing 
(55); and an increased risk for adult-onset asthma (56) and infertility in women and men 
(57;58). 
Cancer 
Obesity confers an increased risk for several types of cancer, e.g. esophageal adenocarcinoma; 
and thyroid, colon, renal, endometrial, and gallbladder cancer. The risk for developing some 
cancers, such as colon cancer, differs among women and men (59;60). The putative 
mechanisms of the relationship between obesity and carcinogenesis include different 
hormonal systems that are interlinked through insulin (59). 
Mortality 
Both overweight and obesity is associated with increased all-cause mortality. In a large study 
of individuals who had never smoked, and did not have heart disease or cancer, mortality was 
lowest with a BMI in the range of 20 – 25 kg/m2 (61). The results were in agreement with a 
study which included smokers and persons with preexisting cancers (62). These recent data 
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contradict earlier reports that failed to show an association between overweight (i.e. BMI 25 – 
30 kg/m2) and increased all-cause mortality (63). 
Life expectancy is decreased in severely obese individuals. In white women aged 20 – 30 
years with a BMI >45 kg/m2, an estimated 8 years of life is lost because of severe obesity, and 
13 years of life is lost for white men in the same age group (64). 
Quality of life 
Previous research has linked obesity and poor physical quality of life in children and 
adolescents. In one study, severely obese children and adolescents had similar health-related 
quality of life as those diagnosed with cancer (65). In adults, an association exists between 
BMI and reduced health-related quality of life, poor physical and mental health, and activity 
limitations (66). Obesity is also associated with psychosocial dysfunction, and more so in 
obese women than in obese men (67). Discrimination of morbidly obese individuals is 
prevalent both at work and in public places (68). Obese persons are also particularly likely to 
encounter negative stigma from family members and health care professionals (69). 
2.1.4 Management 
For patients with obesity-related comorbid conditions, even a modest weight reduction of 
10% or less is associated with important health benefits such as improved glycemic control, a 
reduced blood pressure, and lower cholesterol levels (70). 
Dietary and lifestyle interventions 
In a study conducted in the United States, 44% of women and 29% of men reported that they 
were attempting to lose weight, most commonly by modifying their diet (71). However, only 
about 20% of motivated individuals achieve weight loss maintenance through dietary and 
lifestyle changes (72). In primary care practices, behavioral interventions through in-person 
individual contact or remote weight-loss support, such as e-mail solutions, can induce 
sustained weight loss (73). Commercially available weight loss programs which include 
regular weighing, dietary advice, and physical therapy might provide greater weight loss than 
standard treatment in primary care (74). 
Within 1 year of follow-up, diets which are low in carbohydrate and high in protein lead to 
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greater weight loss and more favorable changes in metabolic parameters in overweight and 
obese individuals than diets which are low in fat and high in carbohydrate (75-77). Also, low-
carbohydrate diets reduce hepatic triglyceride content (78), and have little effect on plasma 
saturated fatty acids concentrations (79). 
Although regular physical activity is commonly recommended for weight loss, clinical 
exercise trials have demonstrated less weight loss effect of such intervention than predicted, 
possibly because of compensatory mechanisms (80). The effects of exercise may be sex-
dependant; exercise of moderate intensity can provide significant weight loss in overweight 
and obese men, whereas it prevents weight gain in women (81). In obese men, weight loss by 
diet and exercise induce greater improvements in insulin action than diet alone (82), whereas 
adding exercise to a diet in obese women does not provide further improvements in metabolic 
markers (83). 
Intensive lifestyle intervention can induce sustained weight loss and improvements in 
cardiovascular and metabolic parameters in overweight and obese individuals with type 2-
diabetes (84). Among severely obese subjects, however, long-term data on the effects of 
lifestyle intervention are limited. Two recent studies suggest that, within 1 year of follow-up, 
intensive lifestyle modification in morbidly obese patients increases physical activity levels, 
substantially reduces weight, and confers positive changes in cardiovascular risk factors and 
glycemic control (85;86).  
Pharmacological treatment 
Anti-obesity drugs provide modest weight loss (<5 kg) compared with placebo after 1 to 4 
years of treatment (87;88). Most studies on such drugs are funded by pharmaceutical 
companies, and attrition rates are generally in the range of 30 – 40%. Thus, poor adherence 
may limit the clinical effectiveness and use of anti-obesity drugs. Changes in cardiovascular 
risk factors and adverse effects differ between the drugs. 
In the Sibutramine Cardiovascular Outcomes (SCOUT) trial, investigators evaluated the 
effect of a serotonin and epinephrine reuptake inhibitor and lifestyle intervention versus 
lifestyle intervention alone in overweight and obese patients, aged 55 years or older, with 
preexisting cardiovascular disease, type 2 diabetes, or both. Sibutramine increased the risk for 
nonfatal cardiovascular events and was consequently withdrawn (89;90). The Comprehensive 
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Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO) 
trial tested whether the selective cannabinoid-1 receptor antagonist rimonabant improved 
major vascular event-free survival in patients with previous established or increased risk for 
vascular disease, but was terminated prematurely because of neuropsychiatric effects of 
rimonabant (91). 
Orlistat is one of few drugs approved for pharmacological weight management. In the 
XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study, orlistat combined 
with lifestyle changes provided significant weight loss and reduced the incidence of diabetes 
in obese subjects with impaired glucose tolerance after 4 years of treatment (92). Recently, 
the U.S. Food and Drug Administration (FDA) approved both the selective serotonin 2C 
receptor agonist lorcaserin and once daily, controlled-release phentermine plus topiramate 
(93;94). These drugs are to be used in obese adults, or in overweight adults with at least one 
obesity-related comorbid condition, in combination with diet and exercise. 
Liraglutide, an analog of the incretin hormone glucagon-like peptide-1 (GLP-1), is approved 
for treatment of type 2 diabetes, but not as an anti-obesity drug. In a recent randomized trial, 
once-daily subcutaneous injections of liraglutide was well tolerated, provided greater weight 
loss than orlistat, and improved cardiovascular risk factors (95). 
2.2 Bariatric surgery 
2.2.1 Surgical techniques 
Jejunoileal bypass 
Studies of the metabolic effects of small bowel bypass in animals were published in the 1950s 
(96). During the next decade, the effects of jejunocolic shunts were reported in morbidly 
obese patients (97). A modified surgical technique, the jejunoileal bypass, was suggested as 
an effective and safe operation for inducing weight loss and was applied throughout the 1970s 
(98-100). This operation combined an end-to-end anastomosis between the proximal jejunum 
and the distal ileum with an anastomosis between the excluded small bowel and the colon to 
decompress the bypassed small bowel and prevent reflux of intestinal content into the 
bypassed segment (101). Long-term follow-up of patients treated with jejunoileal bypass 
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indicates maintained favorable changes in weight and cardiovascular risk factors. However, 
the operation was abandoned because of the risk for serious complications, including protein 
malnutrition, bacterial overgrowth in the bypassed bowel segment, and hepatic failure (2;102-
106). 
Gastric bypass 
Gastric bypass was first performed in 1966 by Edward E. Mason (107). The procedure was 
modeled after a Bilroth II gastrectomy, as weight loss was frequently observed after this 
operation. By constructing a small upper gastric pouch, Mason hypothesized that most 
mucosa containing parietal cells would be located in the distal part of the stomach, thus 
reducing the amount of acid above the stoma. Consequently, meal-stimulated gastrin 
production would be suppressed and the incidence of stomal ulcers would be low (108). The 
anastomosis was initially performed with a narrow gastric outlet and a short proximal loop 
gastroenterostomy placed retrocolically (109). Later modifications of the procedure included 
mobilization of the entire fundus in order to create a smaller gastric pouch (110;111), the 
conversion from loop gastroenterostomy to a Roux-en-Y configuration (112), and the banded 
gastric bypass (the Fobi pouch) (113). 
Gastroplasty 
With the gastroplasty, described in the early 1970s, Mason attempted to simplify the gastric 
bypass (114). The stomach was divided horizontally from the lesser to the greater curvature, 
leaving a small outlet between the upper and lower gastric pouches. However, weight loss 
after the procedure was unsatisfactory. Several surgical modifications were proposed, such as 
gastric partitioning and the vertical banded gastroplasty (115-117).  
Gastric wrapping 
Also preceded by animal studies, the gastric wrapping technique reduced the reservoir 
capacity of the stomach by inverting the lesser curvature by combining a large Nissen’s 
fundoplication and a tightly applied mesh (wrap) around the stomach (118;119). The purpose 
was to develop an alternative bariatric procedure which did not disrupt the continuity of the 
gastrointestinal tract. However, the operation was associated with dysphagia and gastric 
perforations after long-term follow-up (120). 
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Gastric banding 
Building on the principle of reducing the reservoir capacity of the stomach, the first gastric 
banding procedures were performed in 1980 (121). These included the use of a nonadjustable 
band (i.e. a self-lockable nylon band in a Dacron graft). Short-term analyses of weight loss 
were promising, but long-term follow-up demonstrated a high rate of reoperations because of 
esophagitis, weight regain, and also Barrett’s esophagus and erosions of the band through the 
stomach wall (122;123). To overcome complications from tissue reactions of the implanted 
bands, the original bands were replaced by Dacron reinforced silicon bands. The development 
of bands containing an inflatable balloon connected to a subcutaneous reservoir by a tube 
allowed for adjustment of the stoma diameter and pouch size by adding or withdrawing saline 
from the reservoir (124-126).  
Biliopancreatic diversion and duodenal switch 
The purpose of the biliopancreatic diversion procedure, as presented by Scopinaro in 1979, 
was to introduce a safe malabsorptive operation as an alternative to jejunoileal bypass 
(127;128). The main features were a distal gastrectomy to reduce the risk for stomal ulcers, 
and a long Roux-en-Y construction with the enteroenteric anastomosis at 50 cm proximal to 
the ilocecal valve and the gastroenteric anastomosis 250 cm proximal to the valve. Such an 
arrangement would allow for a selective malabsorption of fat, as this is absorbed in the short 
common bowel segment. Protein and starch, however, are absorbed throughout the bowel 
segment between the upper anastomosis and the colon. Mono- and disaccharides, short-chain 
triglycerides, and alcohol are also probably fully absorbed (129).  
A modification of the biliopancreatic diversion, the biliopancreatic diversion with duodenal 
switch, was developed by Hess in 1988 to reduce the risk for complications in patients with 
previous bariatric surgery in the upper part of the stomach (130). This technique, which 
preserves pyloric function, reduced the frequency of complications such as marginal ulcer 
formation and dumping. The duodenal switch included a vertical gastric resection, possibly 
reducing parietal cell mass, along a 40 Fr tube (bougie) from a few centimeters proximal to 
the pylorus to the angle of His. The ileum was anastomosed to the duodenum. 
Cholecystectomy and appendectomy were performed concomitantly. Marceau’s duodenal 
switch procedure, a modification of the biliopancreatic diversion with a sleeve gastrectomy 
and a longer (100 cm) common channel, added further weight loss and reduced the incidence 
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of malnutrition. However, symptoms of abdominal bloating and malodorous stool and flatus 
remained unchanged (131-133). 
Sleeve gastrectomy 
As mentioned, sleeve gastrectomy was proposed as the restrictive feature of the 
biliopancreatic diversion with duodenal switch. Later, in the setting of two-stage laparoscopic 
surgery in high-risk patients, the efficacy of sleeve gastrectomy as a stand-alone bariatric 
procedure was recognized by Gagner and colleagues (134). The procedure was recently 
approved by the ASMBS as an acceptable primary bariatric operation or first operation in a 
staged surgical approach (135). 
Bariatric procedures in current use 
In 2008, gastric bypass accounted for 51% of bariatric procedures performed in North 
America, followed by adjustable gastric banding (44%), sleeve gastrectomy (4%), and 
duodenal switch (1%). Correspondingly, in Europe, adjustable gastric banding procedures 
were performed in 43% of patients, followed by gastric bypass (39%), sleeve gastrectomy 
(7%), and duodenal switch (5%) (136). Today, most procedures are done by laparoscopy. In 
recent years, banding procedures are performed less in Europe whereas gastric banding and 
sleeve gastrectomy are done with increasing frequency in North America (19). Laparoscopic 
gastric bypass is the most commonly performed procedure in Norway, although laparoscopic 
sleeve gastrectomy is gaining popularity. Duodenal switch is offered at some centers, both by 
laparoscopy and by open technique, and accounts for about 5% of bariatric procedures at Oslo 
University Hospital Aker (137;138). 
2.2.2 Laparoscopy in bariatric surgery 
The first laparoscopic bariatric procedures were performed in the early 1990s. Reports of 
laparoscopically placed nonadjustable and adjustable gastric bands (139;140) were followed 
by studies of the first vertical banded gastroplasty in 1993 (141), laparoscopic gastric bypass 
in 1994 (142), and laparoscopic duodenal switch in 2000 (143). Studies comparing open 
versus laparoscopic bariatric surgery suggest that weight loss is similar with both approaches. 
The advantages of laparoscopic surgery include a shorter length of hospital stay, less 
postoperative pain, an improved cosmetic result, swifter return to daily activities, and reduced  
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Figure 1. Bariatric surgical procedures in current use. Reproduced from DeMaria (144) with 
permission. Top left: Laparoscopic adjustable gastric banding, top right: vertical (sleeve) 
gastrectomy, bottom left: Roux-en-Y gastric bypass, bottom right: biliopancreatic diversion 
with duodenal switch. 
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rates of wound infections and incisional hernias (145-150). In a meta-analysis comparing 
open and laparoscopic bariatric surgery, investigators found no differences in the risks for 
reoperation, anastomotic leak, or mortality between the two approaches (151). 
Learning curve in laparoscopic bariatric surgery 
After the introduction of laparoscopy in surgical procedures such as appendectomy, 
cholecystectomy, and colorectal resections, surgical learning curves for the operations were 
described. The acquisition of surgical skills is reflected in shortened lengths of surgery and 
postoperative hospital stay (152-154). However, the number of procedures reported as 
sufficient for proficiency in a procedure vary widely and are limited by various definitions of 
a “learning curve”, by reports of results from a surgical team rather than a single surgeon, and 
by categorizing procedural volumes instead of exploring the effects of procedure volumes as a 
continuous variable in analyses (155). Also, several reports of learning curves in laparoscopic 
surgery were published in the early era of laparoscopy. The learning curve for laparoscopic 
cholecystectomy, for example, has been described to comprise 25 cases, but further 
improvement is observed beyond 200 cases (156). For laparoscopic gastric bypass, 
investigators have reported that the learning curve comprises about 100 cases (157). 
2.2.3 Outcomes after bariatric surgery 
Weight loss 
In a meta-analysis of bariatric surgery published in 2004 which included 22094 patients, the 
mean percent of excess weight lost (i.e. weight loss/excess weight*100%) was 48% after 
gastric banding, 62% after gastric bypass, and 70% after biliopancreatic diversion with or 
without duodenal switch (158). In another meta-analysis, weight loss was also greatest after 
biliopancreatic diversion, followed by gastric bypass (159). Studies of weight loss outcome 
after gastric bypass after 5 years of follow-up are shown in Table 2 (articles were retrieved 
through a nonsystematic search in PubMed). 
Diabetes 
In 1995, investigators found that in a cohort of over 600 morbidly obese patients undergoing 
gastric bypass, glucose levels were normalized in 121 of 146 patients (83%) with type 2 
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diabetes after up to 14 years of follow-up (162). A later meta-analysis showed that 78% of 
patients with type 2 diabetes had normalized glucose levels after bariatric surgery (176). The 
prevalence of type 2 diabetes in 136 patients operated at Oslo University Hospital Aker was 
34% before and 10% after a mean of 17 months after gastric bypass (47). The beneficial effect 
of surgery on glucose levels varies with the surgical techniques. Young patient age and short 
duration of diabetes is associated with the highest remission rates (176-178). Recently, the 
International Diabetes Federation acknowledged that bariatric surgery can be considered an 
appropriate treatment for obese subjects with type 2 diabetes who do not reach treatment 
goals with medication (179). 
A substantial proportion of patients with type 2 diabetes may discontinue antidiabetic 
medication shortly after bariatric surgery (180). Animal studies indicate that this may in part 
be attributed to the rerouting of nutrients from the upper gastrointestinal tract (foregut 
exclusion theory) (181). Other investigators have shown that the early improvement in insulin 
resistance is primarily a result of caloric restriction and an increased nutrient delivery to the 
hindgut (hindgut delivery theory) (182;183). Increased meal stimulated release of hormones 
from the hindgut is observed after surgical techniques that include foregut exclusion and those 
that do not (184). Gastric bypass is associated with increased postprandial concentrations of 
gut hormones such as peptide YY (PYY) and GLP-1, primarily released from the distal bowel 
(185). GLP-1 exerts numerous effects on the pancreas and different peripheral tissues 
resulting in increased insulin sensitivity (186). Over time, weight loss in itself will have a 
positive effect on insulin resistance. 
Cardiovascular risk 
Bariatric surgery is associated with amelioration of a wide range of risk factors for heart 
disease and predicts a substantial long-term cardiovascular risk reduction (187;188). 
Evaluation of changes in cardiovascular risk after bariatric surgery was reported from the 
Swedish Obese Subjects (SOS) study. This is a nonrandomized, matched, prospective trial 
including 4047 patients of whom 2010 have had bariatric surgery and 2037 serve as controls. 
At 2 and 10 years of follow-up, risk factors such as diabetes, hypertriglyceridemia, low levels 
of HDL cholesterol, and hypertension changed more favorably in the surgery group than in 
the control group (166). After a mean follow-up of 15 years, the number of cardiovascular 
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deaths was significantly lower in the surgery group (28 events versus 49 events in the control 
group) (189).  
Cancer 
In the SOS study, after a mean follow-up of 11 years, a significantly lower number of first-
time cancers were observed in the surgery group than in the control group. A reduced cancer 
incidence was observed in women, but not in men. This sex-specific difference in cancer 
incidence was also reported in a study from the Utah Cancer Registry. 6596 patients who had 
undergone gastric bypass and 9442 severely obese persons who had applied for driver’s 
licenses were matched for age, sex, and BMI (190). After a mean follow-up of 13 years, the 
surgery group had a 24% lower incidence of cancer and a 46% lower cancer mortality. The 
reduction in cancer incidence was greatest for obesity-related types of cancer. This finding 
was later supported by others (191). 
Mortality 
Three retrospective studies published between 1997 and 2004 indicated a reduced mortality 
after bariatric surgery by reducing the risks for a number of conditions such as cardiovascular 
disease and cancer (192-194). In 2007, one large retrospective study and a report from the 
SOS study supported these findings, although the absolute differences in mortality were 
relatively small between the surgery and control groups in both studies (195;196). There is a 
majority of women in most case series in the bariatric literature, but a later study found a 
survival benefit also in male patients (197). However, in an analysis of a cohort of high-risk 
patients (predominantly older men), bariatric surgery was not associated with decreased 
mortality (198). 
Other conditions associated with obesity 
Bariatric surgery is associated with an improvement of obstructive sleep apnea syndrome 
(158;199) and reduced hip and knee pain in patients with osteoarthritis (200). Fertility can 
improve in women after surgically induced weight loss, including in patients with polycystic 
ovarian syndrome (201;202). Also, evidence suggests that rates of adverse maternal and 
neonatal pregnancy outcomes are reduced in women who have had bariatric surgery 
18 
 
compared with rates in nonoperated obese (203). Of concern, some case reports indicate a 
worsening of sperm parameters in morbidly obese men after bariatric surgery (204;205). 
Quality of life 
Morbidly obese patients seeking bariatric surgery have reduced health-related quality of life 
and experience great improvements after surgery (66;206). This is reported across different 
procedures such as gastric bypass and duodenal switch (207;208). After jejunoileal bypass, 
patient satisfaction was also surprisingly good in spite of high rates of complications and 
readmissions (110).  
Procedure-related morbidity and mortality 
Complications after bariatric procedures include gastrointestinal leaks and bleeding, 
anastomotic strictures, internal small bowel herniation, and cholelithiasis (209;210). In a 
prospective, multicenter study of 30-day outcomes in 4776 patients after gastric bypass 
(mostly performed by laparoscopy) and laparoscopic adjustable gastric banding, 4.3% of 
patients had a major adverse event and the mortality rate was 0.3% (18).  
There is no agreement on how to define complications after bariatric surgery. Rates of 
complications occurring within 30 days after laparoscopic gastric bypass are reported in the 
range of 13% – 17% (157;211). Recent studies from high-volume Scandinavian hospitals 
indicate that this operation may be performed with extremely low morbidity rates (1% – 3%) 
(212;213). In an analysis of data from an ASMBS database containing 57918 operations, 
mostly performed by laparoscopy, the morbidity rate after sleeve gastrectomy was higher than 
after gastric banding and lower than after gastric bypass (17). 
In general, laparoscopic duodenal switch case series are smaller than series of laparoscopic 
gastric bypass and the morbidity rates are higher. In a series of 1000 open and laparoscopic 
duodenal switch operations, 30-day rates of “minor” and “major” complications after the 
laparoscopic approach were 8% and 7%, respectively (214). In another series, the 30-day 
morbidity rate after laparoscopic duodenal switch was 24% in patients with a BMI 50 kg/m2 
(215), similar to the 25% morbidity rate after this operation at Oslo University Hospital Aker 
(138).  
19 
 
In a 2007 meta-analysis, 30-day mortality rates were lower after laparoscopic gastric bypass 
(0.16%) than after laparoscopic biliopancreatic diversion with or without duodenal switch 
(1.1%) (216). In a recent survey of 28616 operations from hospitals accredited by the 
American College of Surgeons (ACS) – Bariatric Surgery Center Network, the 30-day 
mortality rate after laparoscopic sleeve gastrectomy (0.11%) was positioned between 
laparoscopic gastric banding (0.05%) and laparoscopic gastric bypass (0.14%) (19). 
Outcome after bariatric surgery is influenced by hospital and surgeon procedure volume, with 
lowest morbidity and mortality rates in high-volume centers (217-219). In the 2000s, studies 
raised concerns about high mortality rates after bariatric surgery, particularly for older 
patients (220). In a large gastric bypass case series published in 2002, male gender and 
superobesity were identified as predictors of severe complications, and patients >55 years had 
a threefold-higher mortality rate than younger patients (221). In a recent large series, an 
extreme BMI value was associated with an increased risk for 30-day major complications, 
whereas patient age and sex was not (18). 
Nutritional and metabolic complications 
Low concentrations of several vitamins, such as vitamin B-6, vitamin C, 25-hydroxyvitamin 
D, and vitamin E are common in morbidly obese patients opting for bariatric surgery (222). 
Close follow-up of patients after surgery is required to prevent vitamin deficiencies (223-
225). High doses of supplementation of fat-soluble vitamins have been proposed after 
duodenal switch (226). Deficiencies of iron and other micronutrients are common after both 
gastric bypass and malabsorptive surgery (129;225-230). Protein-calorie malnutrition can be 
severe after malabsorptive surgery, particularly in patients with a short common channel (50 
cm) (129;231). In rare cases, transient hepatic impairment or death from liver failure develops 
after malabsorptive procedures (232;233). Patients usually respond to treatment with dietary 
changes or parenteral nutrition, but 1 – 5% eventually require revisional surgery with 
lengthening of the small bowel available for nutrient uptake (226;231). Hyperinsulinemic 
hypoglycemia (233), kidney stones and oxalate nephropathy (226;234;235), and visual 
impairment (236;237) are also known metabolic sequelae after bariatric surgery. 
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Eating behavior  
Although limited, available research indicates that laparoscopic adjustable gastric banding is 
associated with positive changes in eating behavior (238). However, undesirable eating 
patterns such as grazing (i.e. continuous eating of small amounts of food over long periods of 
time) are frequent (239). For gastric bypass surgery, a high ability to intentionally limit food 
intake (i.e. cognitive restraint) before surgery is associated with greater weight loss after the 
operation (240). Some studies suggest that gastric bypass is associated with improvements in 
undesirable eating patterns and, as compared with purely restrictive procedures, a reduced 
consumption of high-fat foods and an increased intake of fruits and vegetables (241-243). 
However, bulimic episodes, vomiting, and food aversions are not uncommon (244;245). 
Malabsorptive operations also seem to confer positive changes in eating behavior (246). 
Gastrointestinal symptoms and bowel function 
After gastric bypass, early dumping is common within 15 – 30 minutes after meals containing 
sugar (247). Postprandial sweating and nausea has been attributed to rapid emptying of 
hyperosmolar foods to the jejunum, followed by a fluid shift into the gut lumen, a fall in 
plasma volume, and sympathetic stimulation from pressoreceptors (248). Late dumping 
syndrome is characterized by symptoms such as diaphoresis and impaired consciousness 1 – 3 
hours after meals (233). Excessive nausea and vomiting after surgery can cause severe 
malnutrition and possibly neurological sequelae (249). After gastric bypass, patients can 
experience relief of a range of gastrointestinal symptoms in the long-term, whereas duodenal 
switch has been associated with diarrhea, abdominal bloating, and foul-smelling gas and stool 
(226;250).  
2.2.4 Weight loss after bariatric surgery in morbidly versus 
superobese patients 
Gastric bypass 
Reports of long-term weight loss results after gastric bypass have demonstrated that a 
substantial proportion of superobese patients may still be morbidly obese even after peak 
weight loss. For example, one study found that 43% of patients with a preoperative  
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BMI >50 kg/m2 had a BMI >35 kg/m2 approximately 2 years after surgery (163). Other 
reports of long-term results support these findings (170). 
Distal gastric bypass   
Sugerman and colleagues reoperated patients who had insufficient weight loss or correction of 
comorbid conditions after gastric bypass by performing a so-called distal gastric bypass, with 
a shorter common channel for nutrient uptake. Five of the patients had a 50 cm common 
channel, and all these eventually had severe protein-calorie malnutrition demanding revisional 
surgery and two died of hepatic failure (251). Most other published results after distal gastric 
bypass, but not all (252), show an increased weight loss and risk for complications related to 
malnutrition (253-257). Apparently, applying a very long alimentary limb in a distal gastric 
bypass somewhat reduces the risk for serious malnutrition. Nelson et al described a very, very 
long-limb gastric bypass in a report of 257 patients, mostly with a BMI >50 kg/m2 (235). This 
technique comprises a common channel length of 100 cm, a biliopancreatic limb of 60 cm, 
and an alimentary limb of 300 to 500 cm. After an average of 4 years of follow-up, over 80% 
of patients had lost more than 50% of excessive weight. Patient satisfaction was high although 
4% had revisional surgery for protein-calorie malnutrition. 
Gastric bypass versus duodenal switch 
Meta-analyses have indicated that weight loss is greater following duodenal switch than 
gastric bypass (158;159), but few studies have directly compared these procedures. Some 
nonrandomized comparisons show that weight loss is greater after duodenal switch than after 
gastric bypass (258;259). Others have reported similar weight loss after the procedures (260). 
We sought to compare surgical treatment of superobesity with gastric bypass versus duodenal 
switch in a randomized trial. 
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3 Aims 
The aims of this thesis were to evaluate results after establishing a laparoscopic gastric bypass 
program for the treatment of morbid obesity and to compare outcome of gastric bypass and 
duodenal switch, both performed by laparoscopy, in superobese patients. This included: 
I An evaluation of perioperative outcome and learning curves for two surgeons during 
the introduction of laparoscopic gastric bypass at a Norwegian hospital. 
II A comparison of perioperative safety and 1-year weight loss after laparoscopic gastric 
bypass and laparoscopic duodenal switch in superobese patients. 
III A study of 2-year weight loss and changes in cardiovascular risk factors and quality of 
life after gastric bypass and duodenal switch in superobese patients.  
IV An evaluation of changes in gastrointestinal symptoms, bowel function, eating 
behavior, dietary intake, and psychosocial functioning 2 years after gastric bypass and 
duodenal switch in superobese patients. 
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4 Methods 
4.1 Patients and study designs 
4.1.1 Paper I 
Morbidly obese patients undergoing bariatric surgery at Oslo University Hospital Aker from 
June 2004 until October 2007 were evaluated for inclusion in the study. A total of 292 
consecutive patients undergoing laparoscopic gastric bypass were included. Patients were 
excluded if they had biliopancreatic diversion with duodenal switch (n=31), sleeve 
gastrectomy (n=20), or gastric banding (n=1); or had previously undergone bariatric surgery 
(n=11).  
Data were retrieved retrospectively from patient charts from June 2004 to December 2005. 
Subsequently, data were collected prospectively on designated case forms. They were stored 
in a database containing perioperative and follow-up data of all bariatric patients operated at 
Oslo University Hospital Aker. 
4.1.2 Papers II – IV 
Patients included in a randomized trial of laparoscopic gastric bypass versus laparoscopic 
duodenal switch were recruited from referrals to treatment of morbid obesity at Oslo 
University Hospital Aker and Sahlgrenska University Hospital, Gothenburg, Sweden between 
March 2006 and August 2007. Participants were eligible for inclusion if they had a BMI of 50 
– 60 kg/m2 at referral, were aged 20 – 50 years, and had failed attempts of previous weight 
loss. Exclusion criteria were a history of previous bariatric or major abdominal surgery, 
disabling cardiopulmonary disease, cancer, long-term oral steroid treatment, and conditions 
associated with poor compliance (such as drug abuse or severe psychiatric illness). A signed, 
informed consent was retrieved from all participants. Participants were consulted, informed, 
and enrolled by dedicated persons at both centers. 
A total of 368 patients were prescreened for inclusion (261). 68 patients fulfilled the inclusion 
criteria and 7 of these declined to participate. 61 patients were included and randomized.  
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Randomization 
Patients were randomly assigned to laparoscopic gastric bypass or laparoscopic duodenal 
switch at Sahlgrenska with the LabView software, version 7.1 (National Instruments, Austin, 
Texas) with stratification according to hospital, patient sex, age (<35 years or 35 years), and 
BMI (<55 kg/m2 or 55 kg/m2) by using the minimization method. Blocking was not used. 
Patients and surgeons were masked to treatment allocation until 1 week before surgery. 
Surgical interventions 
The patients consumed a low-calorie diet (1000 kcal/d) for 3 weeks before surgery. 
Operations were performed at both study hospitals with standardized laparoscopic techniques. 
Total intravenous anesthesia with target-controlled infusion was used for both procedures. 
Bupivacaine was injected at the trocar sites at the start of the procedure. During surgery, 500 
ml dextran was infused as thrombosis prophylaxis, and single prophylactic doses of 1500 mg 
metronidazole and 400 mg doxycycline were administered. In both procedures, 
pneumoperitoneum was established by visual introduction of the first trocar 15 cm below the 
xiphoid. The limb lengths were measured by sequentially placing a 20 cm band adjacent to 
the small bowel. Mesenteric defects were not closed in either procedure. 
In gastric bypass, five trocars were placed and the liver was mobilised with a retractor. The 
stomach was divided proximally with a gold (3.8 mm) or blue (3.5 mm) linear stapler 
cartridge to create a small pouch of about 25 mL. The jejunum was measured 50 cm from the 
ligament of Treitz and anastomosed to the pouch in an antecolic antegastric fashion with a 45 
mm long blue stapler cartridge. The anastomosis was completed with running suture. The 
omentum was not routinely transected. To create the alimentary limb, the jejunum was 
measured 150 cm distally from the gastrojejunal anastomosis and anastomosed to the 50 cm 
biliopancreatic limb using a 45 mm long white (2.5 mm) stapler cartridge and closed with 
running suture. The small bowel was then transected between the 2 anastomoses with a white 
stapler cartridge to create a Roux-en-Y configuration with a long common channel, allowing 
food from the alimentary limb to be mixed with bile and pancreatic juices transported in the 
biliopancreatic limb. The patency and run-off of the gastrojejunostomy was evaluated by 
instilling diluted methylene blue in a nasogastric tube while clamping the small bowel. 
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In the duodenal switch, an additional 5 mm trocar was placed below the umbilicus. A sleeve 
gastrectomy was performed along a nasogastric tube of 30 – 32 Fr with repeated firings of 60 
mm long green (4.1 mm), gold or blue stapler cartridges from the antrum to the angle of His. 
The duodenum was mobilized and transected 4 cm distal to the pylorus with a 60 mm blue 
cartridge. The small bowel was measured from the cecum to create a common channel of 100 
cm and an alimentary limb of 200 cm. The procedure then involved a hand-sewn anastomosis 
between the duodenum and the ileum, an anastomosis between the biliopancreatic limb and 
the ileum with a 45 mm long white stapler cartridge and closed with a running suture, and 
transection of the bowel between the anastomoses. A cholecystectomy was performed in 
patients with symptomatic gallstone disease. Appendectomy was not performed. 
Postoperative care 
The patients consumed a liquid diet from the first postoperative day, a semiliquid diet after 1 
week, with a gradual return to normal food intake after 2 weeks. Low molecular weight 
heparin was administered daily according to weight from the day after the procedure until 10 
days after discharge. The patients were discharged by the attending bariatric surgeon. 
Postoperative outpatient follow-up was at 6 weeks, 6 months, and 1 and 2 years by surgeon 
and dietician. 
Nutritional supplements 
One week after surgery, all patients were prescribed daily supplements of multivitamins, 100 
mg of iron sulfate, 1000 mg of calcium carbonate, and 20 ȝg of vitamin D3. Patients in the 
gastric bypass group also received injections of vitamin B12 every 3 months. 
Ursodeoxycholic acid (500 mg/day) was prescribed for 6 months, except in participants who 
had had a cholecystectomy. 
After surgery, patients received relevant top-up vitamin supplementation if concentrations 
were below these cutoffs: thiamine, 55 nmol/L; vitamin B6, 11 nmol/L; vitamin C, 11 ȝmol/L; 
vitamin A, 0.9 ȝmol/L; 25-hydroxyvitamin D, 37 nmol/L; and vitamin E, 2.2 ȝmol/mmol 
(adjusted for serum total cholesterol and triglycerides) (262). Blood samples were repeated 
after 4 to 6 weeks. Top-up supplementation was discontinued if the vitamin concentration was 
within the reference interval. 
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4.2 Outcome measures 
4.2.1 Paper I 
As indicators of the surgical learning curve, the lengths of surgery and postoperative hospital 
stay, and 30-day rates of morbidity, reoperations, and readmissions were evaluated. The 
learning curve was assessed by the graphs as the point at which all indicators amenable for 
graphical analysis had levelled off. Previous reports have indicated that the length of the 
learning curve for laparoscopic gastric bypass is about 100 procedures. We aimed to compare 
surgical results from the early and late phases of the learning curve and chose to compare the 
first 40 and last 40 procedures by the surgeons individually. We also compared the first 100 
with the subsequent procedures for both surgeons to evaluate the results from procedures 
performed prior to and following completion of the learning curve for laparoscopic gastric 
bypass. 
4.2.2 Papers II – IV 
The primary end point of the randomized study of laparoscopic gastric bypass versus 
laparoscopic duodenal switch in superobese patients was the change in BMI from baseline 
until 2 years after surgery. Secondary end points included changes in anthropometric 
measures, cardiovascular risk factors, health-related quality of life, body composition, vitamin 
concentrations, and adverse events (papers II and III). Paper IV presents other secondary end 
points, i.e. gastrointestinal symptoms, bowel function, eating behavior, dietary intake, and 
psychosocial functioning. 
Weight was measured with patients wearing light clothing and no shoes, with 1 kg subtracted 
to account for clothing. Weight change was reported as reduction in BMI units, percent of 
excess BMI lost ([preoperative BMI - current BMI]/[preoperative BMI - 25]  100%), total 
weight loss in kilograms, and percent of body weight loss. The number of participants who 
were classified as class III obese (BMI 40 kg/m2) at 2 years after surgery was also evaluated. 
Waist circumference was measured halfway between the caudal point of the costal arch and 
the iliac crest (263). Hip circumference was measured at the level of the femoral great 
trochanters. With patients in the supine position, sagittal abdominal diameter was measured as 
the distance from the back to the highest point of the abdomen during normal expiration, as a 
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proxy for visceral adipose tissue mass (264). Cardiovascular risk factors were evaluated by 
changes in fasting lipid concentrations (total cholesterol, high-density lipoprotein cholesterol, 
low-density lipoprotein [LDL] cholesterol, and triglycerides), glucose, insulin, C-reactive 
protein (CRP), and blood pressure. Blood pressure was measured 3 times with an 
appropriately sized cuff after the participant had rested for 5 minutes, and the last 2 
measurements were averaged. Comorbid conditions were diagnosed on the basis of referrals 
and clinical assessment.  
Blood samples were collected after overnight fast. Routine laboratory analyses (glucose, 
lipids, and CRP) were performed at the Departments of Clinical Chemistry at the two study 
sites. Hitachi Modular multi-analyzers (Boehringer Mannheim, Germany) were used for these 
analyses (Model 717 at Oslo University Hospital Aker and 800 at Sahlgrenska University 
Hospital). Intact parathyroid hormone was measured by chemi-luminoimmunometric assay 
(Diagnostic Products Corporation, Los Angeles, California) at the Hormone Laboratory, Oslo 
University Hospital. Insulin was measured with different immunoassays at Sahlgrenska 
(Insulin Elecsys, Roche Diagnostics GmbH, Mannheim, Germany) and at Oslo University 
Hospital Aker (Linco Research Inc, St. Charles, Missouri before March 2007 and DELFIA, 
PerkinElmer Life Sciences, Wallac Oy, Turku, Finland in subsequent analyses). Detailed 
descriptions of vitamin assays used in the study have been published elsewhere (262). 
Body composition was evaluated by changes in fat mass and fat-free mass, as measured by 
bioelectrical impedance analysis in Norwegian participants (n=30; 2 participants exceeded the 
200 kg weight capacity of the apparatus at baseline) by using the BC-418 (Tanita, Tokyo, 
Japan). In Swedish participants (n=30), total body potassium was estimated as a proxy for fat-
free mass by measuring the amount of radioactive K-40 in a whole-body counter (Nuclear 
Enterprises, Edinburgh, United Kingdom) at the Department of Radiation Physics at 
Sahlgrenska University Hospital. The ratio of total body potassium to fat-free mass was set at 
64.8 mmol/kg for men and 59.6 mmol/kg for women (265). The percent of weight lost as fat-
free mass ([ǻfat-free mass/ǻbody weight] x 100%) was calculated after both body 
composition studies. 
Health-related quality of life instruments are commonly divided into generic (i.e. not specific 
to age, disease, or treatment group) and condition-specific (266). Generic health-related 
quality of life was assessed by using validated Norwegian and Swedish versions of the Short 
Form-36 Health Survey (SF-36) (4-week recall, version 2.0). This self-administered 
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questionnaire consists of 8 domains, of which 4 reflect physical health and 4 reflect mental 
health. A score was calculated for each domain on a scale from 0 (worst possible health state) 
to 100 (best possible health state) (266). 
Psychosocial function was evaluated by the Obesity-related Problems scale (OP scale). This is 
a condition-specific quality of life measure which consists of eight items on a 4-point 
response scale. It is validated for measuring the effect of obesity on psychosocial functioning 
and useful for evaluating effects of obesity interventions (67). The participants were asked 
how bothered they were by their obesity in everyday life activities (e.g. private gatherings, 
going to restaurants or community activities, trying on and buying clothes, and intimate 
relations). The responses were summed and the score was transformed to a scale from 0 to 
100, where a high score indicates more psychosocial dysfunction. 
Gastrointestinal symptoms were evaluated by the Gastrointestinal Symptom Rating Scale 
(GSRS), which is a validated measure of perceived severity of gastrointestinal symptoms 
(267;268). The GSRS consists of 15 items; each measured on a 7-point Likert scale where 1 
represents no symptoms and 7 denotes the most severe symptoms. Mean values for 5 
symptom dimensions (i.e. diarrhea, indigestion, constipation, abdominal pain, and reflux) 
were calculated. 
The participants’ bowel function was assessed with a validated questionnaire developed for 
patients with fecal incontinence and constipation (269), and later modified at Sahlgrenska. 
The participants were asked about frequency and texture of stool, sensibility for stool, 
discrimination between gas and stool, deferring time, involuntary leakage of gas, anal leakage 
of stool, use of pads, physical and social impact of bowel habits, and medication. 
The Three-Factor Eating Questionnaire-R21 (TFEQ-R21) is validated for measuring eating 
behavior in obese persons (270). TFEQ-R21 includes three domains: uncontrolled eating (9 
items, the tendency to lose control over eating when feeling hungry or when exposed to 
external stimuli), cognitive restraint (6 items, the conscious restriction of food intake to 
control body weight or body shape), and emotional eating (6 items, overeating in relation to 
negative mood states) (271;272). The domain scores range from 0 to 100. A high score 
indicates more uncontrolled, restraint, or emotional eating. 
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The participants recorded their ingested foods and drinks for 4 consecutive days (3 weekdays 
and 1 weekend day). They were encouraged to continue normal eating habits. They were also 
instructed to express quantities in common household measures and to provide detailed 
descriptions of the food items and the preparation of the food. The food records were checked 
for incomplete data (e.g. type of food or portion size). The total caloric intake and intakes of 
fat, protein, and carbohydrates were calculated using the DIET32 software (Aivo, Solna, 
Sweden) with a nutrient database from the Swedish National Food Composition Tables 
(Livsmedelsdatabas [PC-kost], Statens Livsmedelsverk 1993).  
4.3 Statistics 
4.3.1 Sample size calculation 
In the randomized trial, the sample size was based on changes in the BMI from baseline until 
2 years after surgery (primary endpoint). In a review of superobese patients treated at 
Sahlgrenska, the mean (standard deviation [SD]) reductions in BMI were 18.0 (6.7) kg/m2 
after gastric bypass (n=19) and 24.9 (5.0) kg/m2 after duodenal switch (n=13) after mean 
follow-ups of 34 and 31 months, respectively. Thus, 26 participants would give 80% power to 
detect a significant difference between the groups (P<0.050). A total of 60 participants were 
included to strengthen analysis of secondary outcome. Sample size was calculated in 
SamplePower 2.0 (SPSS, Chicago, Illinois). 
4.3.2 Statistical analyses 
Proportions were presented as numbers or numbers (%). Continuous data were presented as 
mean (SD) or median (range). 
Proportions between groups were compared with the chi-square test, the Fisher’s exact test or 
the Suissa–Shuster exact unconditional test. In paper IV, the bowel function questionnaire 
included outcomes with four ordered categories. After assigning the categories the scores (1, 
2, 3, 4), outcomes were compared between the two treatment groups using the exact 
Wilcoxon-Mann-Whitney test. 
In paper I, the association between two continuous variables was estimated with Spearman 
correlation. To graph the curve for the estimated odds ratio for complication related to patient 
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BMI, a logistic regression model was used to estimate the odds ratio for complication with a 
95% confidence interval, adjusted for age, gender, number of procedures, length of surgery, 
and surgeon. The odds ratio for complication related to patient age was adjusted for BMI, 
gender, number of procedures, length of surgery, and surgeon. To graph the probability 
curves of perioperative complications, the operation dates were sorted in increasing order for 
each surgeon. The increasing orders were saved in a new variable called “number of 
procedures”. The probability of complications as a function of surgeon experience was 
estimated by fitting regression spline curves using the R software function “smooth.spline”, 
which fits piecewise cubic polynomials to the data. 
In papers I and II, a Student’s t test or a Mann-Whitney U test (if a normal distribution could 
not be assumed after logarithmic transformation) was used to compare continuous variables. 
In papers III and IV, linear mixed models were fitted to all continuous outcome variables to 
account for the repeated measures by patient. Competing models were compared by using the 
Akaike information criterion and the Bayesian information criterion. Time was modeled by 
using a piecewise linear spline with a knot at 12 months. Individual participant time points, 
measured as the number of weeks since inclusion, were used. Two variables presented in 
paper III (glucose and insulin) had a knot at 6 months instead of 12 months, and 2 variables 
(systolic and diastolic blood pressures) were modeled with only 1 slope. 
In paper III, time and time-by-treatment interaction were fixed effects in all models. All 
models included a random intercept. For some variables, models also included fixed effects 
for treatment and site and random slopes by patient. In paper IV, all models included fixed 
effects for treatment, time, and time × treatment interaction. For some variables, models also 
included fixed effects for site. All models included a random intercept and random effects for 
time, except the TFEQ-R21 dimension emotional eating, which only included a random 
intercept. An unstructured covariance matrix was used in all models, except for the GSRS 
dimension diarrhea, which had an independent covariance matrix structure. 
Statistical analyses were performed with SPSS version 15.0 for Windows (SPSS, Chicago, 
Illinois), Stata version 11.1 (StataCorp, College Station, Texas), and StatXact 9 (Cytel, 
Cambridge, Massachusetts). Graphs were created with the R software, version 2.6.0 for 
Windows (R foundation for Statistical Computing, Vienna, Austria) and SigmaPlot 10.0 
(Systat Software Inc, San Jose, California). A 2-sided P value <0.05 was considered 
statistically significant.  
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4.4 Ethics 
The patient database used in paper I was approved and licensed by The Norwegian Data 
Protection Agency. A signed, informed consent was obtained from included patients. 
The randomized trial was approved by the regional committees for medical and health 
research ethics in South-Eastern Norway and in Gothenburg, Sweden. All patients were 
carefully informed about the potential benefits and common complications following 
laparoscopic gastric bypass and laparoscopic duodenal switch. A signed, informed consent 
was obtained from all included patients. The trial was registered at ClinicalTrials.gov 
(registration number: NCT00327912) and supported by research grants from the South-
Eastern Norway Regional Health Authority and Sahlgrenska University Hospital. The funding 
sources had no role in the design of the study; collection, analysis, and interpretation of the 
data; or drafting of the manuscripts. 
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5 Results 
5.1 Paper I 
Establishing laparoscopic Roux-en-Y gastric bypass: perioperative outcome 
and characteristics of the learning curve 
This study presents the 30-day outcome after laparoscopic gastric bypass and the learning 
curves for two surgeons while introducing laparoscopic bariatric surgery at Oslo University 
Hospital Aker. The morbidity rate in the series of 292 primary procedures was 15%, and there 
was no mortality. All primary procedures, and many reoperations, were completed by 
laparoscopy. A high patient age, but not a high BMI, was associated with an increased risk for 
complications. Only the lengths of surgery and hospital stay were suitable indicators of a 
learning curve, which comprised about 100 cases per surgeon. 
5.2 Paper II 
Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic 
duodenal switch for superobesity 
In this report from a two-center randomized clinical trial, 60 superobese patients were 
randomized to either laparoscopic gastric bypass or duodenal switch, and followed for 1 year. 
The baseline patient characteristics were similar in the two groups. The changes in BMI and 
percent of excess BMI lost, and the numbers of complications and readmissions, were 
compared between groups. Duodenal switch was associated with significantly longer 
operating time and length of hospital stay. Early (30-day) complications occurred in 4 patients 
after gastric bypass and 7 after duodenal switch, and 4 and 9 patients, respectively, had late 
complications (no significant between-group differences). The mean BMI at 1 year decreased 
significantly more after duodenal switch (55.2 to 32.5 kg/m2) than after gastric bypass (54.8 
to 38.5 kg/m2). 
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5.3 Paper III 
Weight loss, cardiovascular risk factors, and quality of life after gastric bypass 
and duodenal switch: a randomized trial 
This paper reports 2-year weight loss and changes in cardiovascular risk factors and quality of 
life after gastric bypass and duodenal switch (the same patients as presented in paper II). The 
mean reduction in BMI (primary outcome) was significantly greater after duodenal switch 
than after gastric bypass (24.8 kg/m2 versus 17.3 kg/m2). Duodenal switch was also associated 
with significantly greater reductions in total and LDL cholesterol concentrations, 
anthropometric measures, fat mass, and fat-free mass. The reductions in blood pressure and 
mean concentrations of glucose, insulin, and C-reactive protein were not significantly 
different between groups. Concentrations of vitamin A and 25-hydroxyvitamin D were 
reduced after duodenal switch, but not after gastric bypass. SF-36 scores improved in both 
groups, with greater improvement in 1 of 8 domains after gastric bypass. From surgery until 2 
years, a significantly higher proportion of patients had adverse events after duodenal switch 
than after gastric bypass (62% versus 32%). 
5.4 Paper IV 
Gastrointestinal function and eating behavior after gastric bypass and 
duodenal switch 
In this report, 2-year changes in gastrointestinal symptoms, bowel function, eating behavior, 
dietary intake, and psychosocial functioning after gastric bypass and duodenal switch were 
evaluated. The same patients as described in papers II and III completed the GSRS, a bowel 
function questionnaire, the TFEQ-R21, a 4-day food record, and the OP scale. Compared with 
gastric bypass, duodenal switch patients had significantly more symptoms of diarrhea, a 
higher number of defecations at daytime, and more anal leakage of stool after surgery. Scores 
of uncontrolled and emotional eating were significantly and similarly reduced after both 
operations. The mean total caloric intake and intakes of fat and carbohydrates were 
significantly reduced in both groups. Protein intake was significantly reduced only after 
gastric bypass. Psychosocial function was significantly improved after both operations. 
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6 Discussion 
6.1 Methodological considerations 
6.1.1 Methods used in the randomized trial (papers II – IV) 
Age and BMI criteria for inclusion 
In the randomized trial, we included patients aged 20 – 50 years. Consequently, study 
participants were somewhat younger than generally reported in the bariatric literature (158). 
Also, inclusion was limited to patients with a BMI in the range of 50 – 60 kg/m2. The 
rationale for this was that a substantial proportion of gastric bypass patients with a 
preoperative BMI >50 kg/m2 remain morbidly obese after peak weight loss (170). For patients 
with such BMIs, surgical treatments which are perceived to induce greater weight loss are 
sometimes preferred. However, for patients with a preoperative BMI >60 kg/m2, duodenal 
switch may be planned in two stages to reduce morbidity and mortality (143). For study 
purposes, we sought to compare gastric bypass with a one-stage duodenal switch. As a two-
stage duodenal switch algorithm for patients with a BMI >60 kg/m2 is advocated (134), we 
chose to only include participants with BMIs in the range of 50 – 60 kg/m2.  
Two study centers 
Single-center randomized controlled trials report substantially larger intervention effects than 
multicenter trials. Multicenter trials (i.e. 2 different study centers) possibly estimate true 
intervention effects more precisely (273). This may be explained by several factors, such as 
reporting bias (i.e. reports from single-center studies are harder to publish), as shown for drug 
trials (274). Some outcomes in our trial were measured at the two study sites with different 
equipment or techniques (e.g. blood pressure). However, as the study groups were well 
balanced with regard to baseline patient characteristics, and both operations were performed 
at both study sites, we assume that bias because of such differences in measurements is 
relatively small. We analyzed 2-year changes in all outcome variables by study site and 
surgeons (not published). The changes in outcomes differed significantly in 2 variables (hip 
circumference and blood pressure) between study centers. The mean values for both these 
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variables also differed between sites at baseline, which may possibly explain the differences 
in reductions between hospitals, i.e. a regression to the mean.  
Surgical interventions 
At the upstart of the trial, 123 laparoscopic gastric bypass and 15 laparoscopic duodenal 
switch procedures had been performed at Oslo University Hospital Aker and 435 and 18 
procedures, respectively, at Sahlgrenska. Consequently, surgeons at both hospitals were 
relatively less experienced in the surgical aspects of duodenal switch. We speculate that the 
number of laparoscopic duodenal switch operations needed to reach a plateau in operation 
time and a stable low frequency of complications is about the same as for laparoscopic gastric 
bypass. As indicated in Paper I, using operation time and hospital length of stay as indicators, 
a learning curve for laparoscopic duodenal switch might comprise about 100 cases. This 
implies a potential for a lower morbidity rate after duodenal switch than presented in our 
randomized trial. The mean operation time of laparoscopic duodenal switch of 206 minutes in 
our study is close to figures reported by others (275). We have observed a slight reduction in 
the length of duodenal switch surgery after the trial completed (138). The multidisciplinary 
team had relatively less experience with the follow-up of duodenal switch patients. These 
differences in experience with the two procedures should be taken into account when 
interpreting our findings.  
The findings of the study may only be generalizable according to the specific surgical 
techniques described. There is no general agreement on standardization of these techniques. 
Worldwide, a gastric bypass with a small upper gastric pouch and a 150 cm alimentary limb 
length is widely performed. Applying a 150 cm versus a 75 cm alimentary limb might 
increase weight loss in superobese patients (276;277), but the effect of longer limb lengths 
may not be evident after >10 years of follow-up (168). A larger variation of surgical 
technique exists for the duodenal switch which makes direct comparison of results difficult. 
Some surgeons use bougie sizes up to 60 Fr for the sleeve gastrectomy (143). Although we 
constructed the sleeve gastrectomy with a smaller sized tube, the staple lines were not applied 
with tight proximity to the tube, but rather positioned at the border of the lesser curvature 
veins. Further variations of technique include a shorter alimentary limb length, sometimes 
calculated as a percentage of total small bowel length (278), and shorter common channel 
lengths (e.g. 50 or 75 cm) (143;226;275).  
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We did not perform a simultaneous cholecystectomy in any of the procedures. 
Ursodeoxycholic acid prescribed for 6 months after bariatric surgery is effective in reducing 
gallstone formation and routine cholecystectomy during laparoscopic duodenal switch is 
probably not indicated (279;280). 
Power analysis 
As described earlier, sample size was based on expected changes in the primary endpoint 
(BMI) at 2 years after surgery. Results that are not related to the primary endpoint should 
therefore be interpreted cautiously. True differences in secondary outcomes might not have 
been identified because of type II statistical errors.  
Adverse events 
Bariatric surgery is associated with a wide range of surgical, nutritional, and metabolic 
complications. We aimed to register all adverse events by asking patients open-ended 
questions about potential side effects, readmissions, and reoperations at every post-surgical 
visit, as previously suggested (281). This process included retrieving medical notes from other 
hospitals. We did not assess adverse events with a standardized instrument. Systems for 
classifying surgical complications have been proposed, e.g. the Clavien grading system (282), 
but the experience with and validation of such scoring systems in laparoscopic bariatric 
surgery is limited.  
Ethical aspects of randomized studies in bariatric surgery 
Designing randomized trials in bariatric surgery might be considered ethically challenging. 
Comparing medical therapy to bariatric surgery, for example, can raise concern about lack of 
equipoise between treatments (283;284). Further, as patients become familiar with specific 
risks and benefits of surgical procedures, it might be difficult to agree to randomization 
between two different bariatric procedures. 
In 2006, when the first patients were included in our trial, the surgeons involved in the study 
considered both gastric bypass and duodenal switch as acceptable therapeutic options for 
superobese patients. Preoperatively, patients were thoroughly informed about potential 
benefits and side effects of both procedures. Out of a total of 68 patients who received 
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information about the study, only 7 patients eventually declined to participate and 1 patient 
withdrew after randomization. Of interest, in a recently published Swedish randomized trial of 
open gastric bypass versus open duodenal switch, patients increasingly declined to participate, 
resulting in premature closure of inclusion (285). This might indicate that Scandinavian 
patients seeking treatment for morbid obesity have become more conscious about the 
differences in anti-obesity procedures over the last years, coinciding with a large increase in 
procedures performed and broad media coverage of such surgery. 
6.2 Main findings 
6.2.1 Establishing laparoscopic gastric bypass 
We studied results after introducing a laparoscopic gastric bypass program in a hospital with 
no previous institutional experience in bariatric surgery. The surgeons who performed these 
primary operations were experienced in laparoscopy, but had no formal training in bariatric 
surgery. Baseline patient characteristics were comparable to most case series (158). We, and 
others (286;287), have found that a high patient age, but not a high BMI, is associated with an 
increased risk for complications. Thus, BMI might not be a good stratification criterion for 
gastric bypass surgery. In a later report from the Longitudinal Assessment of Bariatric 
Surgery (LABS) consortium, including 4776 primary bariatric operations, extreme BMI 
values, but not age or sex, were associated with an increased risk for complications (18). 
Other studies have suggested that male gender is a predictor of morbidity after gastric bypass 
(221) and that high age is a predictor of mortality (221;288;289).  
There was no mortality in our series of almost 300 operations and the morbidity rate was 
comparable to published series at that time (211). However, it is difficult to evaluate outcome 
across bariatric surgery studies. For example, in large database registries administered by the 
ASMBS and the ACS, the classifications of adverse events and complications differ (17;19). 
In order to monitor the quality of bariatric surgery outcome in Norway, there is a need for a 
national bariatric surgery registry and a standardized collection of data, both in terms of 
which data to collect, and by whom and how data are collected. 
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What is a learning curve? 
There is no clear definition of a learning curve in surgery. Theoretically, the learning curve 
describes operative outcomes of a surgeon until a plateau is reached and further 
improvements are not detectable (290). Aspects such as operating time, risks for minor or 
major complications, rates of conversion to open surgery, and postoperative length of hospital 
stay are commonly evaluated (154;291). Some authors dismiss the concept of a learning curve 
in bariatric surgery all together, pointing out that surgeons are obliged to participate in 
adequate training to ensure that all patients are offered best possible care (292). 
Our study demonstrated that lengths of surgery and hospital stay were indicators of a learning 
curve for laparoscopic gastric bypass, which comprised 100 cases. In a recent review, the 
learning curve was described to include 50 – 100 cases (293). Factors that may reduce the 
length of the learning curve include fellowship or training programs, a stepwise acquisition of 
surgical skills, and high surgical case volumes (212;217;293-296). At present, there is little 
evidence that introducing robotically assisted bariatric surgery confers advantages in terms of 
operation times or morbidity, although the length of the learning curve might be shorter 
(297;298). 
Evidence suggests that patient outcome is improved in high-volume surgical centers (299). At 
Oslo University Hospital Aker today, the procedure volume of 300 cases per year may be 
regarded as high as evaluated by US standards (218). This allows new surgeons to be 
introduced to bariatric surgery by a stepwise learning of the procedures to ensure a low 
morbidity rate, as described by others (296). 
6.2.2 Weight loss after gastric bypass and duodenal switch 
The main finding in papers II – IV is that laparoscopic duodenal switch induces greater 
weight loss than laparoscopic gastric bypass in superobese patients. Two years after surgery, 
1 in 4 patients in the gastric bypass group had a BMI 40 kg/m2. 
Some studies published within the last decade have suggested a greater weight loss effect of 
duodenal switch, but all have been limited by a retrospective design and a possible bias in 
treatment allocation (258;259). Recently, data from another randomized trial evaluating the 
two operations were published. In this study, procedures were performed by open surgery 
with some differences in surgical techniques compared to those described in our trial (285). 
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From a mean baseline BMI of 55 kg/m2 in each group, reductions in BMIs in the groups after 
a mean follow-up of 4 years were very similar to our findings at 2 years.  
Limited data exist on weight loss beyond 10 years after gastric bypass and duodenal switch. 
Available reports are often limited by low rates of follow-up. The patients in the gastric 
bypass group in our trial, with a mean BMI of 38 kg/m2 at 2 years, may expect some regain of 
weight 2 to 10 years after surgery (166;168). In contrast, duodenal switch patients seem to 
experience sustained weight loss over time (300;301), in line with results after biliopancreatic 
diversion (302). Consequently, a relatively large proportion of superobese patients subjected 
to gastric bypass may still be morbidly obese after extended follow-up. Also, the difference in 
weight loss outcome might increase between the operations in favor of duodenal switch. 
6.2.3 Cardiovascular risk factors 
Changes in risk factors for cardiovascular disease have been shown to be linked to the degree 
of weight loss after gastric bypass (303). Despite a large difference in weight reduction 
between the gastric bypass and duodenal switch groups in our trial, the reductions in 
outcomes such as blood pressure and concentrations of glucose, insulin, and CRP were 
similar. Our finding of a greater reduction in LDL cholesterol concentration after duodenal 
switch could mean that patients having this procedure have a greater reduction in long-term 
cardiovascular risk. In a meta-analysis of cholesterol-lowering trials, a 1 mmol/L reduction in 
LDL cholesterol concentration translated into a 12% reduction in total mortality and a 19% 
reduction in coronary mortality over 5 years (304). 
Few participants in our trial had diabetes, possibly because of a relatively young study 
population. Although we found similar reductions in concentrations of glucose and insulin, 
other investigators have reported greater reductions in levels of glucose and HbA1c, and 
greater resolution rates of diabetes, after duodenal switch (285;305). 
The literature contains several reports of high remission rates of hypertension and diabetes 
shortly after bariatric surgery (158;176;306). In three randomized trials, bariatric surgery was 
superior to medical treatment alone in controlling type 2 diabetes (178;307;308). However, 
hypertension and diabetes are progressive diseases that often require more intense treatment 
over time (309-311). The remission rate of diabetes in the SOS study was 72% after 2 years, 
but only 36% at 10 years based on a fasting plasma glucose <7.0 mmol/L and no antidiabetic 
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medication (166). The American Diabetes Association has recently published criteria for 
complete remission of diabetes, defined as a return to normal HbA1c levels and fasting 
glucose <5.6 mmol/L of at least 1 year’s duration in the absence of medication (312). 
According to these criteria, remission rates of diabetes after bariatric surgery are lower than 
previously reported (313). This exemplifies that clinicians and patients must acknowledge that 
amelioration of conditions associated with increased cardiovascular risk might not persist 
after weight loss surgery and that lifelong follow-up is important to ensure adequate 
metabolic control. 
At present, available data indicate that bariatric surgery is associated with clinically important 
long-term improvements in cardiovascular risk and metabolic disturbances 
(166;187;314;315). There is also evidence, albeit limited, of a survival benefit after bariatric 
surgery (195;196). However, the absolute reductions in mortality rates are relatively small. 
After 11 years of follow-up in the SOS study, the absolute difference in mortality was 1.3 
percentage points between the surgically and nonsurgically treated groups (mortality rates of 
5.0% versus 6.3%), yielding a number needed to treat of 76 patients for 1 patient to have a 
survival benefit (316). To investigate whether there is a difference in long-term mortality after 
gastric bypass and duodenal switch requires studies with larger patient groups and extended 
follow-up. 
6.2.4 Nutritional aspects and eating behavior 
Gastric bypass patients had stable or increased concentrations of vitamins after surgery. 
Duodenal switch was associated with a greater risk for deficiencies of vitamin A and 25-
hydroxyvitamin D. Serious nutritional complications, e.g. protein-calorie malnutrition and 
night blindness, only occurred after duodenal switch. These results suggest that patients who 
undergo gastric bypass and duodenal switch probably require different vitamin 
supplementation regimens after surgery. Insufficiencies of fat-soluble vitamins after duodenal 
switch can be treated with high-dose supplementation (317). Dietary adjustment or 
hospitalization for parenteral nutrition is usually sufficient for treating malnutrition (226). 
The results from our trial also indicate that patients should be followed more closely after 
duodenal switch to detect nutritional abnormalities. Compliance with outpatient follow-up 
and vitamin supplementation is particularly important after duodenal switch. Also, because of 
the possible risk for pregnancy-related nutritional deficiencies and adverse neonatal outcomes 
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after duodenal switch, this procedure should probably be used with caution in women of 
childbearing age (203;318). 
Both groups had reductions in the intakes of fat and carbohydrates, but protein intake was 
reduced only after gastric bypass. The greater protein intake after duodenal switch suggests 
that these patients adhered to the recommended high-protein diet after surgery (>90 g/day) 
(319). Although our results showed that duodenal switch patients lost a mean of 5 kg more 
fat-free mass than did gastric bypass patients, the percentage of weight lost as fat-free mass 
did not differ between groups, indicating that duodenal switch patients did not lose 
disproportionally more fat-free mass than gastric bypass patients. 
Our study also indicates that both gastric bypass and duodenal switch confer positive changes 
in eating behavior, with improved scores of uncontrolled and emotional eating. These findings 
are in line with those of others, which also demonstrate a reduced meal size and eating rate, 
and increased meal frequency after gastric bypass (241;320). However, some patients 
experience substantial weight regain after bariatric surgery. Strategies such as self-monitoring 
of food intake and increased physical activity are probably important for improved long-term 
outcome (321). 
6.2.5 Gastrointestinal symptoms 
The rationale for developing the duodenal switch was to reduce the frequency of 
complications of the biliopancreatic diversion, such as marginal ulceration and dumping 
syndrome, by leaving in place the antrum, pylorus, a small segment of duodenum, and the 
lesser curvature of the stomach (130;275;322). Some patients in the duodenal switch group in 
our study reported vomiting, possibly because of a tight sleeve gastrectomy. However, our 
study did not indicate that reflux symptoms were aggravated after duodenal switch. Himpens 
et al have previously shown that a substantial proportion of patients reported de novo 
gastroesophageal reflux symptoms more than 6 years after stand-alone sleeve gastrectomy 
and after duodenal switch (323). Whether there is a difference in reflux symptoms after sleeve 
gastrectomy versus duodenal switch is not known. There is some evidence to suggest a 
beneficial effect of adding a hiatal hernia repair to sleeve gastrectomy in patients with 
gastroesophageal reflux disease (324;325). 
Reflux symptoms improved after gastric bypass in our study, as also shown by others (326), 
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and this procedure may be used as a revisional procedure in sleeve gastrectomy patients with 
severe reflux symptoms (327). After duodenal switch, revisional surgery is most commonly 
performed to correct malnutrition, but also because of gastrointestinal side effects (226;231). 
The effects of bariatric surgery on bowel habits are not clearly defined (328). After duodenal 
switch, several studies have reported an increased frequency of bowel movements in line with 
our results (229;278). Diarrhea after bariatric surgery is a risk factor for fecal incontinence 
(329), and half of duodenal switch patients in our study had anal leakage of stool 2 years after 
surgery. We suggest that duodenal switch should probably not be offered to patients suffering 
from moderate to severe irritable bowel-like symptoms, diarrhea, or fecal incontinence.  
6.2.6 Quality of life 
We found significant and broadly similar improvements in generic health-related quality of 
life in the study groups. In one domain of the SF-36, bodily pain, improvement was greater in 
the duodenal switch group. Although the validity of this specific domain is probably 
acceptable, recent research suggests that physical and mental summary scales, which were not 
calculated in our study, might be preferred to the subscales (330). In other studies of different 
bariatric techniques, patients have reported low SF-36 scores before surgery and large 
improvements within few years after surgery (207;331-333). We found large and similar 
improvements in disease-specific quality of life as measured by the OP scale. In the SOS 
study, weight regain was associated with gradual deterioration of health-related quality of life 
(206). If weight loss is less sustained after gastric bypass than after duodenal switch in the 
long-term, the impact of the operations on quality of life aspects may also differ. 
We did not find any evidence of a negative effect of changes in bowel habits on health-related 
quality of life or psychosocial functioning. However, whether potentially greater 
improvements in quality of life and psychosocial functioning after duodenal switch were 
obscured by negative effects of changes in bowel function is unknown.  
6.3 Who should have bariatric surgery? 
There is no consensus on what constitutes a successful result after bariatric surgery.  The 
literature contains a plethora of definitions. Results are often evaluated according to weight 
changes. In 1982, after analyzing outcome after 29 gastric bypass operations, Reinhold 
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defined an excellent result as having a final weight within 25% of ideal weight (334). Other 
definitions of success include a final BMI <35 kg/m2 for morbidly obese patients and <40 
kg/m2 for superobese patients. A failed result may be defined as failure to achieve a certain 
percentage of weight loss or loss of excessive weight (335;336). The Bariatric Analysis and 
Reporting Outcome System (BAROS) incorporates changes in obesity-related comorbidities, 
complications or reoperations, and a quality of life questionnaire in the evaluation of results 
after surgery (337). 
Without a clear concept of successful and failed therapeutic results after bariatric surgery, the 
indications for bariatric surgery are also not clear-cut. In both the United States and in 
Europe, the associations for bariatric surgeons have recently incorporated the term 
“metabolic” in the names of the organizations, indicating a shift of therapeutic focus from 
weight loss per se to metabolic normalization. Recently proposed obesity staging tools (e.g. 
the Edmonton Obesity Staging System and the King’s Obesity Staging Criteria) may help 
clinicians in selecting patients for surgery according to the severity of obesity-related disease 
(338;339).  
The criteria for bariatric surgery as suggested by the NIH in 1991 should be updated to 
include available knowledge about the specific effects of different bariatric procedures. 
6.4 Clinical implications 
The studies included in this thesis show that weight loss was greater after laparoscopic 
duodenal switch than after gastric bypass in superobese patients. Our findings suggest that a 
relatively large proportion of superobese patients submitted to gastric bypass can still expect 
to be classified as morbidly obese after such surgery. 
Duodenal switch is a technically more challenging operation than gastric bypass. This is 
reflected by a longer operation time and a consistently higher morbidity rate reported in the 
literature. In our study, duodenal switch was associated with greater reductions in some fat-
soluble vitamins, more gastrointestinal side effects, and more adverse events than gastric 
bypass. Both operations were associated with substantial improvements in cardiovascular risk 
factors, improved quality of life, and reduced uncontrolled and emotional eating. 
The potential benefits of duodenal switch surgery with regard to weight loss must be balanced 
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against the higher risk for complications. Until a clear benefit of duodenal switch with regard 
to improved long-term metabolic control or lower mortality has been demonstrated, gastric 
bypass remains a safe surgical option for superobese patients. 
In our opinion, duodenal switch may be offered to carefully selected superobese patients who 
are presumably adherent to follow-up. Duodenal switch should only be performed in 
specialist centers with support of a multidisciplinary team which is familiar with the 
procedure and procedure-specific complications. Currently, laparoscopic duodenal switch is 
performed as a two step procedure at Oslo University Hospital Aker. The aim of this approach 
is partly to ensure that patients are compliant with follow-up after sleeve gastrectomy before 
the malabsorptive component of the procedure (the duodenal switch) is introduced. 
We also suggest that gastric bypass surgery should be limited to high-volume centers in 
Norway. Results included in this thesis have shown that the morbidity rate during the 
introduction of laparoscopic gastric bypass at Oslo University Hospital Aker was acceptable, 
but also that the procedure may result in potentially serious complications and has a long 
surgical learning curve. Our results support the existing literature suggesting that surgeons 
embarking on a career in laparoscopic bariatric surgery need extensive mentoring to acquire 
surgical skills. 
6.5 Topics for further research 
Further follow-up of the randomized trial is warranted to elucidate long-term weight loss, 
metabolic control, and complications in the study groups. As mentioned earlier, gastric bypass 
patients often experience weight regain from a nadir at 1 to 2 years after surgery, and weight 
loss results may increasingly differ between gastric bypass and duodenal switch after longer 
follow-up. 
Our study has shown that duodenal switch is a powerful tool for inducing weight loss. The 
data from our trial combined with other studies indicate that the potential benefit of an 
increased weight loss might be offset by a higher risk for complications and undesirable 
gastrointestinal side effects. Future studies should explore specific long-term effects of gastric 
bypass and duodenal switch, such as effects on vitamin concentrations and bone 
mineralization. Further, data on long-term patient satisfaction after the two surgical 
procedures are scarce.  
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We have initiated a new randomized trial in the surgical treatment of superobesity 
(ClinicalTrials.gov; registration number: NCT00821197). As an extension of the present trial, 
the idea behind this study is to compare potential benefits of a modified gastric bypass 
technique, i.e. the very, very long-limb gastric bypass (235), versus a standard long-limb 
gastric bypass in superobese patients. The aim is to achieve greater weight loss than standard 
gastric bypass in this group of patients, with a maintained low risk for surgical and nutritional 
complications.  
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7 Conclusions 
I Laparoscopic gastric bypass was introduced at Oslo University Hospital Aker with a 
morbidity rate comparable to internationally published results. Lengths of surgery and 
hospital stay were indicators of a learning curve for surgeons, which comprised about 
100 cases. 
In the treatment of superobese patients: 
II Duodenal switch induced a greater weight loss than gastric bypass within 2 years after 
surgery. 
III Changes in other cardiovascular risk factors were similar after gastric bypass and 
duodenal switch, except for greater improvements in mean concentrations of blood 
lipids after duodenal switch. 
IV Laparoscopic gastric bypass and laparoscopic duodenal switch were performed with 
comparable perioperative safety. 
V Duodenal switch was associated with more adverse events at 2 years, more 
gastrointestinal side effects, and greater reductions in mean concentrations of fat-
soluble vitamins. 
VI Both gastric bypass and duodenal switch were associated with a more normalized 
eating pattern and improvements in generic health-related quality of life and 
psychosocial functioning. 
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